CEACAM5 and non-small cell lung carcinoma: Multiple biomarkers, such as carcinoembryonic antigen (CEA), cancer antigen (CA)-199 and cytokeratin-19 fragment antigen 21-1 (CYFRA21-1), have been used in the clinic as markers to monitor the response of NSCLC patients receiving antitumor treatment.